Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

LN-145 or LN-145-S1 in Treating Patients with Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Sarcoma, or Triple-Negative Breast Cancer

Trial Status: closed to accrual

This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, anaplastic thyroid cancer, sarcoma, or triple-negative breast cancer (TNBC) that do not respond to treatment (refractory) or that has come back (relapsed). LN-145 is made by collecting and growing specialized white blood cells (called T-cells) that are collected from the patient's tumor. LN-145-S1 is made using a modified process that chooses a specific portion of the T-cells. The T cells may specifically recognize, target, and kill the tumor cells.